CRNX Crinetics Pharmaceuticals, Inc. - Common Stock
$84,77
Precio · Ago 19, 2026
Fundamentales a fecha de Ago 3, 2026
Rango 52S
$29–$85
100% of range
Calificación del Analista
HOLD
21 analysts
Precio Objetivo
$86
+1% upside
P/E (TTM)
-17.1
ROE
-43.0%
Margen de Beneficio Neto
-6046.2%
Acerca de Crinetics Pharmaceuticals, Inc. - Common Stock Descripción general de la empresa de Wikipedia
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Leer más
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion.
History
Struthers, Zhu, Kusnetzow, and Betz founded Crinetics in 2008 after previously working together on a small molecule drug for the treatment of endometriosis at Neurocrine Biosciences.
Crinetics expanded into a larger laboratory in 2010. After receiving NIH grant funding, Crinetics moved into its second laboratory.
In 2011, Crinetics Pharmaceuticals competed for the Michelson Prize, a competition sponsored by the Found Animals Foundation to develop a low-cost, non-surgical method for sterilizing dogs and cats, which would later lead to the licensing of a molecule for the treatment of acromegaly in large breed dogs.
Crinetics first synthesized its lead drug candidate to treat acromegaly. The drug was named paltusotine, in 2016. Crinetics Pharmaceuticals went public with an IPO in 2018. It conducted Phase II trials for paltusotine from 2019 to 2020. It conducted Phase III trials for paltusotine from 2021 to 2024. After the drug succeeded in a second Phase III study, the FDA accepted the company's new drug application for paltusotine and the company announced it was planning for a 2025 launch for the drug. The FDA set a Prescription Drug User Fee Act for the drug on September 25, 2025.
In 2021, Crinetics, together with 5AM Ventures and Frazier Healthcare Partners, formed an independently operated new company, Radionetics Oncology, aimed to develop a deep pipeline of novel, targeted, nonpeptide radiopharmaceuticals for the treatment of a broad range of oncology indications.
Crinetics partnered with the veterinary medicine company Loyal to develop a pill to extend the lifespans of large dogs in 2023.
In 2024, Scott Struthers received the Ernst & Young Entrepreneur of the Year Award for his work with Crinetics. In 2024, Crinetics was reported to have patent activity in rare diseases, health technology, and addiction therapies.
In 2024, Radionetics formed a strategic relationship with Eli Lilly and Company to take forward Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals. Under the terms of the agreement, Radionetics received a $140 million upfront cash payment. As part of the strategic agreement, Lilly obtained the exclusive right to acquire Radionetics upon conclusion of an exercise period for $1 billion.
Crinetics also established its first office outside the United States in Zug, Switzerland in 2024.
In 2025, Crinetics Pharmaceuticals plans to file an Investigational New Drug for an oral thyroid stimulating hormone receptor antagonist and its nonpeptide drug conjugate (CRN09682). A total of four development candidates are currently in IND-enabling studies, including a PTH antagonist (Hyperparathyrodism), non-peptide drug conjugate (NETs and SST2-expressing solid tumors), TSH antagonist (Graves’ disease & TED) and SST3 agonist (ADPKD).
In July 2026, Vertex Pharmaceuticals agreed to acquire Crinetics for $10 billion.
Treatments
Crinetics’ pipeline focuses on synthesizing novel molecules for rare endocrine diseases. It is most known for developing paltusotine, a drug designed to treat the hormonal disorder acromegaly. Paltusotine works by helping moderate elevated IGF-1 levels, which is the main symptom of acromegaly. Paltusotine has also been tested as a treatment for carcinoid syndrome.
Crinetics has also developed oral treatments for neuroendocrine tumors, hyperinsulism, and Cushing's disease. The company's drug for treating Cushing's disease, Atumeltnant (also known as CRN049894), works by reducing levels of ACTH.
The company's pipeline also includes an oral parathyroid hormone inhibitor program for hyperparathyroidism and treatments for thyroid eye disease, Graves' disease, and obesity. Additionally, Crinetics nonpeptide drug conjugates (NDCs) include CRN09682, which is a somatostatin receptor 2 (SST2) targeted drug. NDCs are a new technology developed in-house by Crinetics.
== References ==
Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗
CRNX Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$84.77
Capitalización Bursátil
$8.10B
P/E (TTM)
-17.1
BPA (TTM)
$-4.95
Ingresos (TTM)
$8M
Rendimiento div.
—
ROE
-43.0%
Deuda/Capital
—
Rango 52S
$29 – $85
CRNX Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$8M
2016-12-31
→
2025-12-31
BPA
$-4.95
2020-12-31
→
2025-12-31
Flujo de caja libre
$-384M
2018-12-31
→
2025-12-31
Márgenes
-6046.2%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
CRNX
Mediana de Pares
P/E (TTM)
-17.1
47.9
P/S (TTM) (P/V (TTM))
1052.7
16.2
P/B (P/C)
8.2
9.3
Price / FCF (Precio / FCF)
-21.1
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
CRNX
Mediana de Pares
Operating Margin (Margen Operativo)
-6714.8%
—
Net Profit Margin (Margen de Beneficio Neto)
-6046.2%
5.1%
ROA
-36.3%
0.81%
ROE
-43.0%
-15.3%
ROIC
-52.1%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
CRNX
Mediana de Pares
Current Ratio (Ratio corriente)
12.3
2.7
Quick Ratio (Ratio Rápido)
12.1
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
CRNX
Mediana de Pares
Revenue YoY (Ingresos interanuales)
640.7%
—
Revenue CAGR 3Y (Ingresos CAGR 3A)
17.6%
—
Revenue CAGR 5Y (Ingresos CAGR 5A)
155.3%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
CRNX
Mediana de Pares
CRNX Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
MANTENER
21 analistas
- Compra fuerte 3 14,3%
- Compra 4 19,0%
- Mantener 14 66,7%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
10 analistas · 2026-08-13
Mediana
$85.00
Media
$85.50
← Por Debajo de Todos los Objetivos
$84.77
Mín
$85.00
Máx
$90.00
Objetivo mediano
$85.00
+0,3%
Objetivo medio
$85.50
+0,9%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.01%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-1.14 | $-1.23 | 0.09% |
| 31 de marzo de 2026 | $-1.23 | $-1.26 | 0.03% |
| 31 de diciembre de 2025 | $-1.29 | $-1.39 | 0.10% |
| 30 de septiembre de 2025 | $-1.38 | $-1.28 | -0.10% |
| 30 de junio de 2025 | $-1.23 | $-1.12 | -0.11% |
| 31 de marzo de 2025 | $-1.04 | $-0.96 | -0.08% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| CRNX | $4.45B | -9.4 | 640.7% | -6046.2% | -43.0% | — |
| CORT | $3.69B | 42.4 | 12.8% | 13.1% | 15.5% | — |
| ELAN | $11.25B | -48.1 | 6.2% | -4.9% | -3.5% | 55.0% |
| AXSM | $9.29B | -49.6 | 65.5% | -28.7% | -227.0% | — |
| LQDA | $3.01B | -43.1 | 1031.2% | -43.5% | -230.0% | — |
| BLTE | — | — | — | — | — | — |
| DFTX | $1.32B | -6.5 | 212.0% | — | -71.0% | — |
| LGND | $3.74B | 30.8 | 60.4% | 46.4% | 13.5% | — |
| AMRX | — | 57.3 | 8.1% | 2.4% | -80.0% | 36.9% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 17
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | $2M | |
| Cost of Revenue | $1M | $0 | $0 | · | · | · | · | · | · | |
| R&D Expense | $332M | $240M | $169M | $130M | $84M | $57M | $42M | $24M | $9M | |
| SG&A Expense | $191M | $100M | $58M | $42M | $25M | $18M | $14M | $7M | $2M | |
| Operating Expenses | $524M | $340M | $227M | $173M | $109M | $75M | $55M | $31M | $11M | |
| Operating Income | $-517M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | $-9M | |
| Interest Expense | · | · | · | · | · | · | · | · | $8.0K | |
| Interest Income | $52M | $41M | $13M | $4M | $157.0K | $991.0K | $3M | $2M | $26.0K | |
| Other Non-op | $-357.0K | $-519.0K | $-159.0K | $5M | $61.0K | $1M | $3M | $2M | $-30.0K | |
| Pretax Income | $-465M | $-298M | $-209M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| Income Tax | $180.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | $-9M | |
| EPS (Basic) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| EPS (Diluted) | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 | $-2.42 | · | · | · | |
| Shares (Basic) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| Shares (Diluted) | 94,057,000 | 80,783,000 | 58,071,000 | 51,982,000 | 38,436,000 | 30,448,000 | · | · | · | |
| EBITDA | $-513M | $-339M | $-223M | $-168M | $-108M | $-75M | $-54M | $-29M | · |
Balance general 24
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102M | $265M | $55M | $33M | $201M | $93M | $40M | $45M | $14M | |
| Short-term Investments | $926M | $1.09B | $504M | $302M | $133M | $78M | $78M | $119M | · | |
| Receivables | $592.0K | $0 | · | · | · | · | · | · | · | |
| Inventory | $2M | $0 | · | · | · | · | · | · | · | |
| Prepaid Expense | $18M | $21M | $16M | $11M | $11M | $7M | $5M | $3M | $973.0K | |
| Other Current Assets | $3M | $2M | $448.0K | $2M | $912.0K | $1M | $668.0K | $876.0K | $239.0K | |
| Current Assets | $1.05B | $1.38B | $574M | $345M | $345M | $177M | $123M | $167M | $15M | |
| PP&E (Net) | $14M | $12M | $11M | $4M | $3M | $3M | $4M | $4M | $400.0K | |
| PP&E (Gross) | $22M | $20M | $16M | $8M | $6M | $6M | $6M | $5M | $704.0K | |
| Accum. Depreciation | $8M | $8M | $5M | $4M | $3M | $3M | $2M | $741.0K | $304.0K | |
| Other Non-current Assets | · | $3M | $2M | $37.0K | $0 | $40.0K | $82.0K | · | $33.0K | |
| Total Assets | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Accounts Payable | $23M | $6M | $7M | $7M | $3M | $6M | $5M | $5M | $403.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | $4M | $179.0K | |
| Current Liabilities | $85M | $60M | $44M | $28M | $16M | $10M | $8M | $8M | $897.0K | |
| Capital Leases | $42M | $45M | $48M | $2M | $3M | $4M | $5M | · | · | |
| Other Non-current Liabilities | $3M | $829.0K | $0 | · | · | · | · | · | · | |
| Total Liabilities | $134M | $110M | $96M | $36M | $19M | $15M | $13M | $11M | $920.0K | |
| Common Stock | · | · | $253.0K | $0 | · | · | · | $24.0K | $1.0K | |
| Retained Earnings | $-1.42B | $-952M | $-654M | $-439M | $-275M | $-168M | $-94M | $-43M | $-16M | |
| AOCI | $2M | $963.0K | $977.0K | $-4M | $-382.0K | $25.0K | $148.0K | $61.0K | · | |
| Stockholders' Equity | $992M | $1.32B | $539M | $316M | $332M | $169M | $117M | $160M | $-15M | |
| Liabilities + Equity | $1.13B | $1.43B | $635M | $352M | $351M | $183M | $130M | $171M | $16M | |
| Shares Outstanding | 95,575,000 | 92,926,000 | 68,175,000 | 53,877,000 | 47,597,000 | 33,001,000 | 24,263,000 | 24,061 | 1,549,575 |
Flujo de Efectivo 13
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $4M | $3M | $1M | $983.0K | $922.0K | $948.0K | $887.0K | $471.0K | $128.0K | |
| Stock-based Comp | $91M | $69M | $41M | $28M | $17M | $10M | $6M | $2M | $271.0K | |
| Deferred Tax | $0 | $0 | $0 | · | · | · | · | · | · | |
| Other Non-cash | $-8M | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $-378M | $-230M | $-169M | $-115M | $-89M | $-62M | $-46M | $-19M | $-9M | |
| CapEx | $6M | $4M | $5M | $2M | $436.0K | $186.0K | $492.0K | $1M | $304.0K | |
| Investing Cash Flow | $174M | $-575M | $-200M | $-174M | $-56M | $217.0K | $42M | $-119M | $-304.0K | |
| Stock Issued | $0 | $985M | $370M | $117M | $250M | $114M | · | $106M | · | |
| Net Stock Activity | $0 | $970M | $369M | $117M | $250M | $114M | · | · | · | |
| Financing Cash Flow | $41M | $1.01B | $391M | $122M | $253M | $115M | $67.0K | $170M | $12M | |
| Net Change in Cash | · | $210M | $22M | $-167M | $108M | $53M | $-5M | $31M | $2M | |
| Taxes Paid | $89.0K | $0 | $0 | · | · | · | · | · | · | |
| Free Cash Flow | $-384M | $-230M | $-171M | $-117M | $-89M | $-62M | $-47M | $-21M | · |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| Net Margin | -6046.2% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| Pretax Margin | -6043.9% | -28720.7% | -5345.9% | -3460.4% | -9985.2% | -103960.6% | -4226.5% | -1116.8% | · | |
| EBITDA Margin | -6664.1% | -32613.5% | -5547.2% | -3544.1% | -9990.9% | -105567.6% | -4512.3% | -1182.5% | · | |
| ROA | -36.3% | -28.8% | -43.5% | -46.6% | -40.3% | -47.0% | -33.4% | -29.0% | · | |
| ROE | -43.0% | -27.7% | -39.5% | -49.1% | -41.0% | -41.4% | -40.9% | -16.6% | · | |
| ROIC | -52.1% | -25.6% | -41.3% | -53.1% | -32.5% | -44.4% | -46.0% | -17.9% | · |
Liquidez y Solvencia 2
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 | 16.9 | 14.8 | 21.0 | · | |
| Quick Ratio | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 | 16.3 | 14.2 | 20.7 | · |
Eficiencia 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | |
| Inventory Turnover | 1.1 | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 26.0 | · | · | · | · | · | · | · | · |
Tasas de Crecimiento 3
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 640.7% | -74.1% | -15.3% | 339.4% | 1418.3% | · | · | · | · | |
| Revenue CAGR 3Y | 17.6% | -1.2% | 283.8% | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 155.3% | · | · | · | · | · | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $8M | $1M | $4M | $5M | $1M | $71.0K | $1M | $2M | · | |
| Net Income TTM | $-465M | $-298M | $-215M | $-164M | $-108M | $-74M | $-50M | $-27M | · | |
| Market Cap | $4.45B | $4.75B | $2.43B | $986M | $1.35B | $466M | $608.8K | $722M | · | |
| P/E | -9.4 | -13.9 | -9.6 | -5.8 | -10.1 | -5.8 | · | · | · | |
| P/S | 578.1 | 4573.0 | 604.5 | 208.1 | 1254.4 | 6558.4 | 0.5 | 297.2 | · | |
| P/B | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | 0.0 | 4.5 | · | |
| P / Tangible Book | 4.5 | 3.6 | 4.5 | 3.1 | 4.1 | 2.8 | · | · | · | |
| P / Cash Flow | -11.8 | -21.0 | -14.6 | -8.6 | -15.3 | -7.5 | -0.0 | -37.1 | · | |
| P / FCF | -11.6 | -20.7 | -14.2 | -8.4 | -15.2 | -7.5 | -0.0 | -35.2 | · | |
| Earnings Yield | -10.6% | -7.2% | -10.4% | -17.2% | -9.9% | -17.2% | · | · | · |
Estado de resultados 15
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $11M | $6M | $143.0K | $1M | $361.0K | $0 | $0 | $399.0K | $640.0K | $0 | $346.0K | $988.0K | $3M | $709.0K | $458.0K | |
| Cost of Revenue | $154.0K | $200.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| R&D Expense | $100M | $100M | $85M | $90M | $80M | $76M | $67M | $62M | $58M | $53M | $46M | $44M | $41M | $38M | $37M | $32M | |
| SG&A Expense | $58M | $51M | $54M | $52M | $50M | $36M | $28M | $26M | $25M | $21M | $17M | $15M | $13M | $12M | $11M | $12M | |
| Operating Expenses | $158M | $151M | $140M | $143M | $130M | $112M | $95M | $88M | $83M | $74M | $63M | $59M | $54M | $51M | $48M | $44M | |
| Operating Income | $-132M | $-140M | $-134M | $-143M | $-129M | $-111M | $-95M | $-88M | $-83M | $-74M | $-63M | $-59M | $-53M | $-48M | $-48M | $-43M | |
| Interest Income | $12M | $13M | $11M | $13M | $13M | $15M | $14M | $11M | $9M | $7M | $7M | $3M | $2M | $2M | $2M | $2M | |
| Other Non-op | $-423.0K | $-131.0K | $-28M | $-49.0K | $20.0K | $-203.0K | $-16M | $-37.0K | $9M | $7M | $-7M | $3M | $2M | $2M | $3M | $2M | |
| Pretax Income | · | · | $-123M | $-130M | · | · | $-81M | $-77M | · | · | · | · | · | · | · | · | |
| Net Income | $-121M | $-128M | $-123M | $-130M | $-116M | $-97M | $-81M | $-77M | $-74M | $-67M | $-60M | $-57M | $-51M | $-46M | $-45M | $-42M | |
| EPS (Basic) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| EPS (Diluted) | $-1.14 | $-1.23 | $-1.30 | $-1.38 | $-1.23 | $-1.04 | $-0.86 | $-0.96 | $-0.94 | $-0.93 | $-0.89 | $-1.01 | $-0.94 | $-0.85 | $-0.83 | $-0.78 | |
| Shares (Basic) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| Shares (Diluted) | 105,560,000 | 104,099,000 | -187,051,000 | 94,215,000 | 93,791,000 | 93,102,000 | -150,605,000 | 80,091,000 | 79,008,000 | 72,289,000 | -106,920,000 | 56,808,000 | 54,275,000 | 53,908,000 | -102,020,000 | 53,768,000 | |
| EBITDA | $-132M | $-140M | · | $-143M | $-129M | $-111M | · | $-88M | $-83M | $-74M | · | $-59M | $-53M | $-48M | · | $-43M |
Balance general 23
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $55M | $114M | $102M | $111M | $54M | $95M | $265M | $317M | $302M | $396M | $55M | $143M | $40M | $41M | $33M | $31M | |
| Short-term Investments | $1.15B | $1.18B | $926M | $981M | $1.14B | $1.18B | $1.09B | $545M | $561M | $505M | · | $412M | $225M | $255M | · | $337M | |
| Receivables | $12M | $6M | $592.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Inventory | $3M | $3M | $2M | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Prepaid Expense | $23M | $22M | $18M | $28M | $20M | $16M | $21M | $15M | $12M | $16M | · | $21M | $20M | $9M | · | $10M | |
| Other Current Assets | $5M | $6M | $3M | $5M | $4M | $3M | $2M | $1M | $2M | $4M | · | $4M | $3M | $3M | · | $2M | |
| Current Assets | $1.24B | $1.32B | $1.05B | $1.12B | $1.22B | $1.29B | $1.38B | $878M | $875M | $917M | · | $576M | $285M | $305M | · | $378M | |
| PP&E (Net) | $13M | $13M | $14M | $14M | $15M | $13M | $12M | $12M | $12M | $12M | · | $10M | $3M | $3M | · | $4M | |
| PP&E (Gross) | $23M | $23M | $22M | $21M | $24M | $21M | $20M | $19M | $18M | $17M | · | $15M | $8M | $8M | · | $7M | |
| Accum. Depreciation | $10M | $9M | $8M | $7M | $10M | $9M | $8M | $7M | $6M | $5M | · | $5M | $5M | $4M | · | $4M | |
| Other Non-current Assets | · | · | · | · | · | $14M | · | $3M | $2M | $2M | · | $2M | $2M | $2M | · | · | |
| Total Assets | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Accounts Payable | $13M | $13M | $23M | $6M | $11M | $10M | $6M | $5M | $9M | $11M | · | $6M | $5M | $6M | · | $6M | |
| Current Liabilities | $80M | $71M | $85M | $74M | $68M | $57M | $60M | $54M | $54M | $52M | · | $40M | $33M | $26M | · | $25M | |
| Capital Leases | $41M | $41M | $42M | $43M | $43M | $44M | $45M | $45M | $46M | $47M | · | $48M | $1M | $2M | · | $2M | |
| Other Non-current Liabilities | $6M | $5M | $3M | $3M | $2M | $2M | $829.0K | $511.0K | $202.0K | · | · | · | · | · | · | · | |
| Total Liabilities | $130M | $121M | $134M | $124M | $118M | $107M | $110M | $104M | $105M | $103M | · | $94M | $39M | $34M | · | $34M | |
| Common Stock | · | · | · | · | · | · | · | · | · | $881.0K | · | · | · | · | · | · | |
| Retained Earnings | $-1.67B | $-1.55B | $-1.42B | $-1.29B | $-1.16B | $-1.05B | $-952M | $-872M | $-795M | $-721M | · | $-594M | $-536M | $-485M | · | $-394M | |
| AOCI | $-3M | $-1M | $2M | $2M | $2M | $2M | $963.0K | $2M | $-190.0K | $150.0K | · | $-865.0K | $-2M | $-3M | · | $-5M | |
| Stockholders' Equity | $1.19B | $1.28B | $992M | $1.07B | $1.17B | $1.25B | $1.32B | $833M | $831M | $875M | $539M | $548M | $254M | $280M | $316M | $351M | |
| Liabilities + Equity | $1.32B | $1.40B | $1.13B | $1.20B | $1.29B | $1.36B | $1.43B | $937M | $936M | $978M | · | $642M | $293M | $314M | · | $385M | |
| Shares Outstanding | 105,808,000 | 105,314,000 | 95,575,000 | 94,548,000 | 94,126,000 | 93,525,000 | 92,926,000 | 80,841,000 | 79,322,000 | 78,539,000 | · | 66,708,000 | 54,682,000 | 53,990,000 | · | 53,796,000 |
Flujo de Efectivo 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $994.0K | $1M | $959.0K | $925.0K | $788.0K | $770.0K | $753.0K | $474.0K | $262.0K | $273.0K | $280.0K | $283.0K | $280.0K | $248.0K | |
| Stock-based Comp | $25M | $30M | $22M | $23M | $26M | $20M | $19M | $18M | $19M | $13M | $12M | $11M | $10M | $8M | $8M | $7M | |
| Operating Cash Flow | $-94M | $-125M | $-93M | $-111M | $-86M | $-88M | $-67M | $-65M | $-48M | $-53M | $-41M | $-41M | $-46M | $-41M | $-35M | $-38M | |
| CapEx | $521.0K | $820.0K | $458.0K | $863.0K | $3M | $1M | $1M | $528.0K | $955.0K | $1M | $935.0K | $4M | $237.0K | $16.0K | $274.0K | $682.0K | |
| Investing Cash Flow | $26M | $-252M | $57M | $165M | $38M | $-86M | $-542M | $21M | $-54M | $309.0K | $-87M | $-193M | $31M | $49M | $37M | $7M | |
| Stock Issued | $0 | $381M | $0 | $0 | $0 | $0 | $544M | $63M | $10M | $383M | $29M | $329M | $11M | $0 | $0 | $-13.0K | |
| Net Stock Activity | · | $381M | · | · | · | $0 | · | · | · | $383M | · | · | · | · | · | · | |
| Financing Cash Flow | $9M | $390M | $26M | $3M | $7M | $4M | $556M | $59M | $8M | $394M | $40M | $338M | $13M | $484.0K | $115.0K | $1M | |
| Net Change in Cash | · | · | · | $57M | $-41M | $-170M | · | $15M | $-94M | $341M | · | $103M | $-2M | $9M | $2M | $-31M | |
| Free Cash Flow | · | $-126M | · | · | · | $-90M | · | · | · | $-54M | · | · | · | $-41M | · | · |
Rentabilidad 6
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| Net Margin | -481.1% | -1191.0% | · | -90972.7% | -11216.0% | -26807.2% | · | · | -18560.1% | -10457.8% | · | -16606.4% | -5159.8% | -1716.9% | · | -9153.9% | |
| Pretax Margin | · | · | · | -90972.7% | · | · | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | -527.4% | -1307.8% | · | -99710.5% | -12523.0% | -30860.1% | · | · | -20747.6% | -11488.9% | · | -17045.4% | -5363.9% | -1790.9% | · | -9487.8% | |
| ROA | -9.3% | -9.3% | · | -12.2% | -10.4% | -8.3% | · | -9.7% | -12.0% | -10.4% | · | -11.2% | -14.3% | -14.2% | · | -14.1% | |
| ROE | -10.2% | -10.1% | · | -13.7% | -11.6% | -9.1% | · | -11.1% | -13.7% | -11.6% | · | -12.8% | -15.9% | -15.8% | · | -15.4% |
Liquidez y Solvencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.6 | 18.6 | · | 15.1 | 17.8 | 22.5 | · | 16.4 | 16.1 | 17.7 | · | 14.2 | 8.7 | 11.6 | · | 15.4 | |
| Quick Ratio | 15.2 | 18.2 | · | 14.7 | 17.5 | 22.2 | · | 16.1 | 15.9 | 17.4 | · | 13.7 | 8.1 | 11.3 | · | 15.0 |
Eficiencia 3
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.1 | 0.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Receivables Turnover | 4.2 | 3.8 | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Valoración (TTM) 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $37M | $12M | · | $2M | $2M | $1M | · | $1M | $2M | $5M | · | $4M | $5M | $7M | · | $4M | |
| Net Income TTM | $-494M | $-470M | · | $-419M | $-363M | $-315M | · | $-275M | $-249M | $-221M | · | $-196M | $-181M | $-165M | · | $-147M | |
| Market Cap | $3.96B | $3.83B | · | $3.94B | $2.71B | $3.14B | · | $4.13B | $3.55B | $3.68B | · | $1.98B | $985M | $867M | · | $1.06B | |
| P/E | -7.5 | -7.4 | · | -9.0 | -6.9 | -8.7 | · | -13.3 | -11.7 | -12.5 | · | -8.3 | -5.3 | -5.1 | · | -6.4 | |
| P/S | 106.9 | 311.8 | · | 2565.4 | 1511.5 | 2240.6 | · | 2982.7 | 1497.2 | 790.1 | · | 443.7 | 215.9 | 129.3 | · | 262.3 | |
| P/B | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Tangible Book | 3.3 | 3.0 | · | 3.7 | 2.3 | 2.5 | · | 5.0 | 4.3 | 4.2 | · | 3.6 | 3.9 | 3.1 | · | 3.0 | |
| P / Cash Flow | · | -30.7 | · | · | · | -35.5 | · | · | · | -69.6 | · | · | · | -21.3 | · | · | |
| P / FCF | · | -30.5 | · | · | · | -35.0 | · | · | · | -67.8 | · | · | · | -21.3 | · | · | |
| Earnings Yield | -13.3% | -13.4% | · | -11.1% | -14.5% | -11.5% | · | -7.5% | -8.5% | -8.0% | · | -12.0% | -18.8% | -19.7% | · | -15.5% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $8M | $1M | $4M | $5M | $1M |
| Margen Operativo % | -6714.8% | -32613.5% | -5547.2% | -3544.1% | -9990.9% |
| Beneficio neto | $-465M | $-298M | $-215M | $-164M | $-108M |
| EPS Diluido | $-4.95 | $-3.69 | $-3.69 | $-3.15 | $-2.80 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ratio corriente | 12.3 | 23.0 | 13.1 | 12.5 | 21.6 |
| Ratio Rápido | 12.1 | 22.7 | 12.7 | 12.1 | 20.9 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-384M | $-230M | $-171M | $-117M | $-89M |
Últimas noticias Noticias recientes que mencionan a esta empresa
- Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal
- Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
- Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
- Why This Pharmaceutical Stock Jumped Close to 100% This Week
- Crinetics Pharmaceuticals (CRNX) is One of the Best AI Driven Biotech Stocks, Here is Why
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 286 declarantes · $3.2B total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 63 (+17 vs trimestre anterior) | 30 (-14 vs trimestre anterior) | 95 (-17 vs trimestre anterior) | 63 (+3 vs trimestre anterior) | +21.6M |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| FMR LLC | $486 250 673 | 12 994 406 | 15,13% | Acciones |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | $336 372 047 | 8 989 098 | 10,46% | Acciones |
| Driehaus Capital Management LLC | $241 866 078 | 6 463 551 | 7,52% | Acciones |
| WELLINGTON MANAGEMENT GROUP LLP | $237 002 526 | 6 333 579 | 7,37% | Acciones |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $180 836 416 | 4 832 614 | 5,63% | Acciones |
| VANGUARD CAPITAL MANAGEMENT LLC | $177 567 704 | 4 745 262 | 5,52% | Acciones |
| STATE STREET CORP | $100 635 477 | 2 689 350 | 3,13% | Acciones |
| Bellevue Group AG | $98 040 400 | 2 620 000 | 3,05% | Acciones |
| BAKER BROS. ADVISORS LP | $87 991 820 | 2 351 465 | 2,74% | Acciones |
| GEODE CAPITAL MANAGEMENT, LLC | $87 542 675 | 2 338 905 | 2,72% | Acciones |
| Polar Capital Holdings Plc | $85 108 460 | 2 274 411 | 2,65% | Acciones |
| Pictet Asset Management Holding SA | $77 572 984 | 2 075 375 | 2,41% | Acciones |
| Siren, L.L.C. | $53 165 887 | 1 420 788 | 1,65% | Acciones |
| First Light Asset Management, LLC | $50 923 606 | 1 360 866 | 1,58% | Acciones |
| NOVO HOLDINGS A/S | $49 394 400 | 1 320 000 | 1,54% | Acciones |
| AMERICAN CENTURY COMPANIES INC | $47 245 129 | 1 262 562 | 1,47% | Acciones |
| ADAR1 Capital Management, LLC | $45 730 234 | 1 222 080 | 1,42% | Acciones |
| DIMENSIONAL FUND ADVISORS LP | $44 555 208 | 1 190 679 | 1,39% | Acciones |
| MONTANOVA CAPITAL, LLC | $44 390 560 | 1 186 279 | 1,38% | Acciones |
| ORBIMED ADVISORS LLC | $37 382 580 | 999 000 | 1,16% | Acciones |
| Hood River Capital Management LLC | $36 259 830 | 968 996 | 1,13% | Acciones |
| GOLDMAN SACHS GROUP INC | $34 657 132 | 926 166 | 1,08% | Acciones |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $32 841 401 | 877 643 | 1,02% | Acciones |
| Aberdeen Group plc | $30 699 181 | 820 395 | 0,95% | Acciones |
| Candriam S.C.A. | $30 618 690 | 819 032 | 0,95% | Acciones |
| VANGUARD FIDUCIARY TRUST CO | $28 230 995 | 754 436 | 0,88% | Acciones |
| Fisher Asset Management, LLC | $27 748 912 | 741 553 | 0,86% | Acciones |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $17 709 036 | 479 400 | 0,55% | Acciones |
| AMERIPRISE FINANCIAL INC | $17 451 149 | 466 356 | 0,54% | Acciones |
| Impax Asset Management Group plc | $16 277 700 | 435 000 | 0,51% | Acciones |
| Prosight Management, LP | $14 020 002 | 374 666 | 0,44% | Acciones |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $13 991 714 | 373 910 | 0,44% | Acciones |
| KENNEDY CAPITAL MANAGEMENT LLC | $13 685 018 | 365 714 | 0,43% | Acciones |
| BRAUN STACEY ASSOCIATES INC | $13 027 511 | 348 143 | 0,41% | Acciones |
| Fiera Capital Corp | $12 395 263 | 331 247 | 0,39% | Acciones |
| BANK OF AMERICA CORP /DE/ | $11 271 877 | 301 226 | 0,35% | Acciones |
| Defilade Capital Management, L.P. | $8 959 845 | 239 440 | 0,28% | Acciones |
| SEB Asset Management AB | $8 003 786 | 213 891 | 0,25% | Acciones |
| Foresite Capital Management VI LLC | $7 933 414 | 212 010 | 0,25% | Acciones |
| RICE HALL JAMES & ASSOCIATES, LLC | $7 346 220 | 196 318 | 0,23% | Acciones |
| TD Asset Management Inc | $7 152 534 | 191 142 | 0,22% | Acciones |
| Swiss National Bank | $6 877 796 | 183 800 | 0,21% | Acciones |
| SEGALL BRYANT & HAMILL, LLC | $6 855 307 | 183 199 | 0,21% | Acciones |
| BlackRock, Inc. | $6 781 290 | 181 221 | 0,21% | Acciones |
| JENNISON ASSOCIATES LLC | $6 056 839 | 161 861 | 0,19% | Acciones |
| New Leaf Venture Partners, L.L.C. | $5 872 650 | 141 000 | 0,18% | Acciones |
| SILVERCREST ASSET MANAGEMENT GROUP LLC | $5 865 136 | 156 738 | 0,18% | Acciones |
| Foresite Capital Management IV, LLC | $5 613 000 | 150 000 | 0,17% | Acciones |
| Bank of New York Mellon Corp | $5 581 754 | 149 165 | 0,17% | Acciones |
| NEW YORK STATE COMMON RETIREMENT FUND | $5 508 898 | 147 218 | 0,17% | Acciones |
| ENVESTNET ASSET MANAGEMENT INC | $5 471 384 | 146 216 | 0,17% | Acciones |
| Moody Aldrich Partners LLC | $5 466 201 | 146 077 | 0,17% | Acciones |
| Ishara Investments LP | $5 369 770 | 143 500 | 0,17% | Acciones |
| CITADEL ADVISORS LLC | $5 176 271 | 138 329 | 0,16% | Acciones |
| RHUMBLINE ADVISERS | $4 861 141 | 129 908 | 0,15% | Acciones |
| ALLIANCEBERNSTEIN L.P. | $4 782 618 | 131 680 | 0,15% | Acciones |
| GordonMD Global Investments LP | $4 751 779 | 126 985 | 0,15% | Acciones |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $4 712 974 | 125 948 | 0,15% | Acciones |
| JANUS HENDERSON GROUP PLC | $4 700 428 | 129 392 | 0,15% | Acciones |
| Cormorant Asset Management, LP | $4 677 500 | 125 000 | 0,15% | Acciones |
| SECTOR GAMMA AS | $4 289 380 | 114 628 | 0,13% | Acciones |
| XTX Topco Ltd | $4 164 547 | 111 292 | 0,13% | Acciones |
| ALPS ADVISORS INC | $3 981 825 | 106 409 | 0,12% | Acciones |
| FEDERATED HERMES, INC. | $3 957 390 | 105 756 | 0,12% | Acciones |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $3 834 048 | 105 563 | 0,12% | Acciones |
| Nuveen Asset Management, LLC | $3 760 151 | 73 541 | 0,12% | Acciones |
| Burkehill Global Management, LP | $3 742 000 | 100 000 | 0,12% | Acciones |
| Nuveen, LLC | $3 619 262 | 96 720 | 0,11% | Acciones |
| VICTORY CAPITAL MANAGEMENT INC | $3 484 251 | 93 112 | 0,11% | Acciones |
| MORGAN STANLEY | $3 320 829 | 88 744 | 0,10% | Acciones |
| TWO SIGMA INVESTMENTS, LP | $3 266 729 | 87 299 | 0,10% | Acciones |
| VANGUARD ASSET MANAGEMENT, Ltd | $3 254 754 | 86 979 | 0,10% | Acciones |
| AWM Investment Company, Inc. | $3 180 700 | 85 000 | 0,10% | Acciones |
| Odyssean, LLC | $3 160 344 | 84 456 | 0,10% | Acciones |
| Affinity Asset Advisors, LLC | $2 806 500 | 75 000 | 0,09% | Acciones |
| ALGERT GLOBAL LLC | $2 714 147 | 72 532 | 0,08% | Acciones |
| ExodusPoint Capital Management, LP | $2 652 404 | 70 882 | 0,08% | Acciones |
| Ensign Peak Advisors, Inc | $2 507 290 | 67 004 | 0,08% | Acciones |
| BARCLAYS PLC | $2 466 127 | 65 904 | 0,08% | Acciones |
| FIRST TRUST ADVISORS LP | $2 370 631 | 63 352 | 0,07% | Acciones |
| Man Group plc | $2 284 229 | 61 043 | 0,07% | Acciones |
| MetLife Investment Management, LLC | $2 258 709 | 60 361 | 0,07% | Acciones |
| CITIGROUP INC | $2 255 229 | 60 268 | 0,07% | Acciones |
| Longaeva Partners L.P. | $2 184 879 | 58 388 | 0,07% | Acciones |
| Swedbank AB | $2 155 392 | 57 600 | 0,07% | Acciones |
| STATE OF WISCONSIN INVESTMENT BOARD | $2 068 016 | 55 265 | 0,06% | Acciones |
| Jump Financial, LLC | $1 923 388 | 51 400 | 0,06% | Acciones |
| Lighthouse Investment Partners, LLC | $1 871 000 | 50 000 | 0,06% | Acciones |
| Vestmark Advisory Solutions, Inc. | $1 823 252 | 48 724 | 0,06% | Acciones |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $1 787 254 | 47 762 | 0,06% | Acciones |
| VANGUARD GROUP INC | $1 774 626 | 38 123 | 0,06% | Acciones |
| Point72 Asset Management, L.P. | $1 735 577 | 46 381 | 0,05% | Acciones |
| BNP PARIBAS FINANCIAL MARKETS | $1 696 398 | 45 334 | 0,05% | Acciones |
| RAYMOND JAMES FINANCIAL INC | $1 606 254 | 42 925 | 0,05% | Acciones |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1 549 188 | 41 400 | 0,05% | Opción de compra |
| Invesco Ltd. | $1 545 446 | 41 300 | 0,05% | Acciones |
| Vanguard Global Advisers, LLC | $1 485 986 | 39 711 | 0,05% | Acciones |
| HighMark Wealth Management LLC | $1 444 224 | 38 595 | 0,04% | Acciones |
| OAK RIDGE INVESTMENTS LLC | $1 405 046 | 37 548 | 0,04% | Acciones |
| Orion Porfolio Solutions, LLC | $1 404 234 | 37 526 | 0,04% | Acciones |
Informantes de la empresa 20 insiders · 9 directivos · 10 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Tobin Schilke | Chief Financial Officer | 10 de marzo de 2025 A | 52 000 | 0 | 0 | $0 |
| Marc Wilson | CFO | 26 de septiembre de 2024 M | 111 092 | 0 | 0 | $0 |
| Jeff E. Knight | Chief Operating Officer | 19 de marzo de 2025 S | 87 491 | 0 | 0 | $0 |
| Stephen F. Betz | Chief Scientific Officer | 12 de junio de 2025 M | 99 713 | 0 | 0 | $0 |
| Dana Pizzuti | Chief Med and Dev Officer | 19 de marzo de 2025 S | 72 233 | 0 | 0 | $0 |
| Isabel Kalofonos | Chief Commercial Officer | 10 de enero de 2025 A | — | 0 | 0 | $0 |
| James Hassard | Chief Commercial Officer | 5 de julio de 2024 M | 29 259 | 0 | 0 | $0 |
| Alan Seth Krasner | Chief Medical Officer | 17 de octubre de 2023 M | 43 210 | 0 | 0 | $0 |
| Ajay Madan | Chief Development Officer | 28 de febrero de 2022 A | 176 995 | 0 | 0 | $0 |
| Coelho Rogerio Vivaldi | Consejero | 2 de julio de 2026 S | 19 225 | 0 | 1 | $-120 000 |
| Caren Deardorf | Consejero | 18 de junio de 2026 A | 22 225 | 0 | 0 | $0 |
| Weston Nichols | Consejero | 18 de junio de 2026 A | 22 225 | 0 | 0 | $0 |
| Stephanie Okey | Consejero | 18 de junio de 2026 A | 12 325 | 0 | 2 | $-246 143 |
| Matthew K Fust | Consejero | 18 de junio de 2026 A | 28 761 | 0 | 0 | $0 |
| Camille L Bedrosian | Consejero | 18 de junio de 2026 A | 22 225 | 0 | 0 | $0 |
| Wendell Wierenga | Consejero | 18 de junio de 2026 A | 122 071 | 0 | 0 | $0 |
| Wendall Wierenga | Consejero | 11 de junio de 2025 A | 116 146 | 0 | 0 | $0 |
| Stephen W Kaldor | Consejero | 19 de junio de 2020 A | — | 0 | 0 | $0 |
| Jack Nielsen | Consejero | 21 de junio de 2019 A | — | 0 | 0 | $0 |
| Richard Scott Struthers | — | 7 de agosto de 2026 M | 424 706 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 1 tenencia
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Perceptive Advisors LLC, Joseph Edelman, Perceptive Life Sciences Master Fund, Ltd. ×6 presentaciones | 1 de marzo de 2024 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 55 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
| Fondo | Ponderación | Unidades | A fecha de | Fuente |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 2,37% | 107 892 NS | 31 de mayo de 2026 | N-PORT |
| IHE · iShares Trust | 1,95% | 376 636 SH | 8 de agosto de 2026 | Diario |
| FMED · Fidelity Covington Trust | 1,65% | 19 000 NS | 31 de mayo de 2026 | N-PORT |
| PILL · Direxion Shares ETF Trust | 1,40% | 4 666 NS | 30 de abril de 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1,23% | 18 743 NS | 30 de abril de 2026 | N-PORT |
| MMSC · First Trust Exchange-Traded Fund VI… | 0,75% | 11 043 NS | 31 de mayo de 2026 | N-PORT |
| IBB · iShares Trust | 0,63% | 718 323 SH | 8 de agosto de 2026 | Diario |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,60% | 5 737 SH | 8 de agosto de 2026 | Diario |
| IWO · iShares Trust | 0,54% | 940 202 SH | 8 de agosto de 2026 | Diario |
| NUSC · Nushares ETF Trust | 0,28% | 93 045 NS | 30 de abril de 2026 | N-PORT |
| ISCG · iShares Trust | 0,27% | 32 694 SH | 8 de agosto de 2026 | Diario |
| IWM · iShares Trust | 0,27% | 2 625 192 SH | 8 de agosto de 2026 | Diario |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,23% | 110 770 SH | 8 de agosto de 2026 | Diario |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0,20% | 38 553 NS | 30 de abril de 2026 | N-PORT |
| BIB · ProShares Trust | 0,19% | 3 872 NS | 31 de mayo de 2026 | N-PORT |
| ESML · iShares Trust | 0,16% | 55 438 SH | 8 de agosto de 2026 | Diario |
| BKSE · BNY Mellon ETF Trust | 0,15% | 3 142 NS | 30 de abril de 2026 | N-PORT |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,15% | 51 135 SH | 8 de agosto de 2026 | Diario |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,14% | 18 879 NS | 30 de abril de 2026 | N-PORT |
| ISCB · iShares Trust | 0,13% | 4 625 SH | 8 de agosto de 2026 | Diario |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,12% | 596 648 SH | 8 de agosto de 2026 | Diario |
| RSSL · Global X Funds | 0,12% | 42 391 NS | 30 de abril de 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0,11% | 1 399 667 SH | 8 de agosto de 2026 | Diario |
| FFSM · FIDELITY COVINGTON TRUST | 0,10% | 31 759 NS | 30 de abril de 2026 | N-PORT |
| ITWO · ProShares Trust | 0,09% | 4 601 NS | 31 de mayo de 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,09% | 2 909 SH | 8 de agosto de 2026 | Diario |
| SCHA · SCHWAB STRATEGIC TRUST | 0,08% | 492 431 NS | 31 de mayo de 2026 | N-PORT |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 24 991 NS | 30 de abril de 2026 | N-PORT |
| WSML · iShares Trust | 0,07% | 5 742 SH | 8 de agosto de 2026 | Diario |
| FHLC · FIDELITY COVINGTON TRUST | 0,06% | 41 183 NS | 30 de abril de 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,05% | 196 549 NS | 30 de abril de 2026 | N-PORT |
| UWM · ProShares Trust | 0,05% | 3 599 NS | 31 de mayo de 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,05% | 2 419 186 SH | 8 de agosto de 2026 | Diario |
| VHT · VANGUARD WORLD FUND | 0,05% | 275 155 SH | 8 de agosto de 2026 | Diario |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,04% | 5 196 NS | 30 de abril de 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,04% | 1 210 574 SH | 8 de agosto de 2026 | Diario |
| AVIE · AMERICAN CENTURY ETF TRUST | 0,04% | 112 NS | 31 de mayo de 2026 | N-PORT |
| URTY · ProShares Trust | 0,04% | 3 643 NS | 31 de mayo de 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,02% | 5 689 NS | 31 de mayo de 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,02% | 3 773 NS | 31 de mayo de 2026 | N-PORT |
| HDG · ProShares Trust | 0,02% | 91 NS | 31 de mayo de 2026 | N-PORT |
| ITOT · iShares Trust | 0,01% | 146 419 SH | 8 de agosto de 2026 | Diario |
| IWV · iShares Trust | 0,01% | 27 043 SH | 8 de agosto de 2026 | Diario |
| DFAC · Dimensional ETF Trust | 0,01% | 125 853 NS | 30 de abril de 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,01% | 3 342 704 SH | 8 de agosto de 2026 | Diario |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,01% | 8 345 SH | 8 de agosto de 2026 | Diario |
| ESGV · VANGUARD WORLD FUND | 0,01% | 22 843 SH | 8 de agosto de 2026 | Diario |
| ONEQ · Fidelity Commonwealth Trust | 0,01% | 28 694 NS | 31 de mayo de 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 5 863 NS | 30 de abril de 2026 | N-PORT |
| TILT · FlexShares Trust | 0,01% | 3 388 NS | 30 de abril de 2026 | N-PORT |